Tivic Health Systems (TIVC) Q3 2024 earnings summary

Executive summary

• Focused on three strategic pillars: ClearUP product profitability, advancing non-invasive vagus nerve stimulation (VNS) research, and streamlining operations.

• Significant progress reported in product relaunch, clinical trials, and cost reductions.

• Leadership transition with Lisa Wolf appointed as Interim CFO, bringing extensive financial experience.

• The company continues to invest in R&D, focusing on non-invasive VNS clinical research and product development.

• Substantial doubt exists about the company's ability to continue as a going concern over the next 12 months without additional capital.

Financial highlights

• Q3 2024 revenue was $126,000, down 56% year-over-year, primarily due to a 55% decrease in units sold.

• Gross profit for Q3 was $44,000, with a gross margin of 35%; nine-month gross profit was $241,000.

• Operating expenses for Q3 2024 were $1.5 million, down from $1.9 million in Q3 2023.

• Net loss for Q3 was $1.4 million, improved from $1.8 million in Q3 2023.

• Cash and cash equivalents at quarter-end were $2.2 million, with working capital of $2.6 million.

Outlook and guidance

• ClearUP expected to grow organically, with focus shifting to VNS program for future growth.

• Anticipates sharing more specific commercial strategies for VNS by end of year or early next year.

• Exploring alternative monetization for ClearUP, including licensing and white labeling.

• Management expects continued variability in sales due to reduced marketing spend and macroeconomic uncertainty.

• Additional capital will be required to fund operations, R&D, and commercialization efforts over the next 12 months.